Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma

AIM: To investigate the associations between the polymorphisms of cell cycle pathway genes and the risk of hepatocellular carcinoma(HCC). METHODS: We enrolled 1127 cases newly diagnosed with HCC from the Tumor Hospital of Guangxi Medical University and 1200 non-tumor patients from the First Affiliat...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 22; no. 24; pp. 5558 - 5567
Main Authors Nan, Yue-Li, Hu, Yan-Ling, Liu, Zhi-Ke, Duan, Fang-Fang, Xu, Yang, Li, Shu, Li, Ting, Chen, Da-Fang, Zeng, Xiao-Yun
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 28.06.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:AIM: To investigate the associations between the polymorphisms of cell cycle pathway genes and the risk of hepatocellular carcinoma(HCC). METHODS: We enrolled 1127 cases newly diagnosed with HCC from the Tumor Hospital of Guangxi Medical University and 1200 non-tumor patients from the First Affiliated Hospital of Guangxi Medical University. General demographic characteristics, behavioral information, and hematological indices were collected by unified questionnaires. Genomic DNA was isolatedfrom peripheral venous blood using Phenol-Chloroform. The genotyping was performed using the Sequenom Mass ARRAY i PLEX genotyping method. The association between genetic polymorphisms and risk of HCC was shown by P-value and the odd ratio(OR) with 95% confidence interval(CI) using the unconditional logistic regression after adjusting for age, sex, nationality, smoking, drinking, family history of HCC, and hepatitis B virus(HBV) infection. Moreover, stratified analysis was conducted on the basis of the status of HBV infection, smoking, and alcohol drinking.RESULTS: The HCC risk was lower in patients with the MCM4 rs2305952 CC(OR = 0.22, 95%CI: 0.08-0.63, P = 0.01) and with the CHEK1 rs515255 TC, TT, TC/TT(OR = 0.73, 95%CI: 0.56-0.96, P = 0.02; OR = 0.67, 95%CI: 0.46-0.97, P = 0.04; OR = 0.72, 95%CI: 0.56-0.92, P = 0.01, respectively). Conversely, the HCC risk was higher in patients with the KAT2 B rs17006625 GG(OR = 1.64, 95%CI: 1.01-2.64, P = 0.04). In addition, the risk was markedly lower for those who were carriers of MCM4 rs2305952 CC and were also HBs Ag-positive and non-drinking and nonsmoking(P < 0.05, respectively) and for those who were carriers of CHEK1 rs515255 TC, TT, TC/TT and were also HBs Ag-negative and non-drinking(P < 0.05, respectively). Moreover, the risk was higher for those who were carriers of KAT2 B rs17006625 GG and were also HBs Ag-negative(P < 0.05).CONCLUSION: Of 12 cell cycle pathway genes, MCM4, CHEK1 and KAT2 B polymorphisms may be associated with the risk of HCC.
Bibliography:Yue-Li Nan;Yan-Ling Hu;Zhi-Ke Liu;Fang-Fang Duan;Yang Xu;Shu Li;Ting Li;Da-Fang Chen;Xiao-Yun Zeng;Department of Epidemiology, School of Public Health, Guangxi Medical University;Medical Scientific Research Centre, Guangxi Medical University;Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center;Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: Zeng XY designed the research; Xu Y, Li S and Li T collected the materials and clinical data; Liu ZK and Duan FF performed the majority of experiments; Chen DF conceived the experimental assays; Nan YL performed the experiments, analyzed the data and wrote the manuscript; Hu YL made critical revisions of the manuscript.
Correspondence to: Xiao-Yun Zeng, MD, PhD, Department of Epidemiology, School of Public Health, Guangxi Medical University, No. 22 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. zxyxjw@21cn.com
Telephone: +86-771-5358325 Fax: +86-771-5352523
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v22.i24.5558